TMS for Depression: Could a Simple Coil Change Offer New Hope?
"Exploring the Impact of Different TMS Coil Designs on Treatment Outcomes for Refractory Depression"
In the relentless battle against depression, finding effective treatments is often a deeply personal journey. For many, the path leads to transcranial magnetic stimulation (TMS), a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. But what if the key to unlocking even greater success lies in a seemingly small detail – the design of the TMS coil itself? Recent research suggests this might be the case, opening up new avenues of hope for those who find traditional treatments less effective.
This article explores the nuances of TMS, specifically focusing on a comparison between two common coil designs: the figure-8 coil and the double-cone coil. We'll unpack the latest findings, the science behind these differences, and what they could mean for the future of depression treatment. Our goal is to provide you with clear, accessible information, empowering you to have informed conversations with your healthcare provider and to understand the potential benefits of different approaches.
This article focuses on a recent study, providing a clear, easy-to-understand overview of how different TMS coil designs can impact treatment for depression. We will explore the science behind the different coils and what these findings could mean for patients and their healthcare providers, always keeping the focus on helping the patient.
TMS in Practice
Transcranial Magnetic Stimulation (TMS) is used as an alternative treatment for several treatment-resistant psychiatric disorders, although the 2021 ten-year review noted that information about daily clinical practice remained limited. The National Center for Health Research reports that TMS devices had stimulated the brains of tens of thousands of patients in the United States, often for refractory depression. It also reports that the FDA cleared TMS devices for market in 2008 through the de novo pathway. More recent real-world reporting from LifeStance describes outcomes involving more than 350 patients with treatment-resistant depression in outpatient settings.
How TMS Is Delivered
TMS is a non-invasive treatment in which an electromagnetic coil placed on the scalp induces a focal, patterned electric current in the cerebral cortex. The Clinical TMS Society describes this current as temporarily modulating localized cortical activity. A 2025 consensus review used a modified Delphi process and reviewed 2,396 abstracts and manuscripts to develop updated guidance on TMS safety, efficacy, and clinical use for depression. The same consensus literature identifies targeting methods, special populations, and accelerated protocols as areas requiring further exploration, while a 2025 comparison study specifically examined accelerated versus standard or sham repetitive TMS.
From Discovery to Clinical Use
The history of TMS is described as a sequence of advances beginning with electromagnetic induction and progressing through noninvasive motor-cortex stimulation, safety standards for repetitive dosing, randomized depression trials, and device-specific FDA authorizations. ScienceInsights dates TMS's development to the 1980s, when it began evolving from a research tool into an FDA-cleared depression treatment covered by insurance. The historical account from Los Altos Neurology likewise identifies randomized depression trials and later FDA authorizations for additional indications and treatment schedules as key milestones. These sources present TMS as the product of roughly 190 years of scientific development, from foundational electromagnetic research to modern treatment protocols.
Figure-8 vs. Double-Cone Coils: What's the Difference, and Why Does It Matter?
At the heart of TMS lies the coil – the device placed against the scalp to generate magnetic pulses. The two main coil types, figure-8 and double-cone, differ significantly in their design and the way they interact with the brain. The figure-8 coil, known for its precision, targets a smaller, more focused area of the brain, making it ideal for specific applications. However, the double-cone coil, while less precise, can reach deeper brain structures and potentially stimulate a larger area.
- Motor Threshold (MT): The minimal intensity of stimulation needed to trigger a response (e.g., muscle movement).
- Figure-8 Coil: Targets a smaller, more focused area; often requires higher intensity.
- Double-Cone Coil: Stimulates a larger area; may reach deeper brain structures.
- Study Findings: Double-cone coils may require a lower intensity than figure-8 coils to achieve the same effect.
- Implications: These findings could influence treatment protocols and patient outcomes.
An Evolving Evidence Base
Recent work continues to examine how TMS protocols can be optimized for depression. Research attention includes treatment targeting, accelerated schedules, and comparisons with standard or sham protocols. Because no source material was provided for this subsection, specific conclusions about newer efficacy estimates or preferred protocols cannot be drawn here.
Limits and Tradeoffs
TMS is presented as a non-invasive option that may ease depression when medications have not worked, but that possibility does not mean it succeeds for every patient. The available source material explicitly frames TMS as a treatment whose advantages and disadvantages should be weighed before starting. Questions about treatment fit, expected benefit, and practical drawbacks therefore remain part of clinical decision-making rather than reasons to treat TMS as a universal replacement for medication. The supplied sources do not provide a specific failure rate or a detailed list of unsuccessful outcomes.
TMS Among Treatment Options
TMS is compared with medication and psychotherapy as an FDA-approved alternative for people who do not obtain sufficient relief from traditional approaches. The 2026 comparison of treatment-resistant depression alternatives identifies medication switching, Spravato or ketamine, electroconvulsive therapy, psychotherapy, and trial-stage psilocybin data as other options. A separate 2026 comparison focuses specifically on ketamine versus TMS, including their mechanisms, FDA status, speed of relief, remission rates, cost, insurance coverage, and side effects. The source material therefore supports viewing TMS as one option within a broader treatment landscape, not as a universally superior intervention.
Looking Ahead: The Future of TMS and Depression Treatment
The findings comparing figure-8 and double-cone coils are a promising step toward personalized TMS treatment. While more research is needed to confirm these findings and explore their long-term impact, the study underscores the importance of considering every aspect of treatment. As research continues, we can expect to see even more refined approaches to TMS, helping more individuals find relief from the burden of depression. If you are considering TMS, discuss these findings with your doctor. The future of depression treatment is not one-size-fits-all – it’s about finding the right fit for you.
What Experts Conclude
The Clinical TMS Society consensus review summarizes published clinical trials to assess the safety and efficacy of TMS for depression in routine practice. A separate account reports that an updated consensus statement was produced by a panel of 18 expert clinicians and researchers, replacing 2018 guidance. That account says the panel concluded that TMS continues to have broad evidence supporting safety and efficacy. Together, these sources describe expert support for TMS while emphasizing systematic review of the clinical evidence.
Toward Faster and More Personalised TMS
Future TMS research is focused on clarifying the treatment's current status, guiding scientific application, and supporting innovation in antidepressant therapy. Accelerated TMS is an emerging application intended to reduce treatment length and improve response time. A 2026 comprehensive review describes TMS as a safe and effective neuromodulatory intervention, particularly for treatment-resistant depression, while noting that differences in efficacy, sustainability of treatment effects, and patient-specific outcomes across protocols remain under investigation. These directions suggest that the next phase of development will depend on determining which protocols work best for particular patients.
Access and Treatment Burden
Unlike medications, TMS does not cause systemic side effects such as weight gain or fatigue, according to the University of Texas Health Science Center at Houston. However, treatment is typically delivered in a clinic five days a week for several weeks, creating a substantial time and access commitment. The same source says an expert panel reviewed nearly 2,400 studies and confirmed that TMS is safe and effective, including for people whose depression had not responded to medications. A recent review likewise describes repetitive TMS as an effective and safe treatment for major depressive disorder, while noting that its clinical history includes nearly 30 years of investigation.
From Stories to Shorter Regimens
Patient stories and breakthrough cases are commonly used to describe the reported life-changing impact of TMS for depression, although such accounts are not substitutes for controlled clinical evidence. Conventional TMS regimens require weeks of clinic visits, according to a real-world case-series report. That report describes the ONE-D regimen, an optimized neuroplasticity-enhanced depression treatment delivering 600-pulse intermittent theta-burst stimulation at 120% of motor threshold while targeting the left dorsolateral prefrontal cortex. The authors presented it as a single-day therapeutic course in an open-label case series, so its results should be interpreted as early real-world evidence rather than definitive proof of general effectiveness.